1-4 of 4
Kenneth Chan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy

Reda Z. Mahfouz, Ania Jankowska, Quteba Ebrahem, Xiaorong Gu, Valeria Visconte, Ali Tabarroki, Pramod Terse, Joseph Covey, Kenneth Chan, Yonghua Ling, Kory J. Engelke, Mikkael A. Sekeres, Ramon Tiu, Jaroslaw Maciejewski, Tomas Radivoyevitch, Yogen Saunthararajah
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (4): 938–948.
https://doi.org/10.1158/1078-0432.CCR-12-1722
Published: 14 February 2013
View article titled, Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy
Open the PDF for Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy in another window
Includes: Supplementary data
Journal Articles

Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia

Rebecca B. Klisovic, William Blum, Xiaohui Wei, Shujun Liu, Zhongfa Liu, Zhiliang Xie, Tamara Vukosavljevic, Cheryl Kefauver, LeNguyen Huynh, Jiuxia Pang, James A. Zwiebel, Steven Devine, John C. Byrd, Michael R. Grever, Kenneth Chan, Guido Marcucci
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (12): 3889–3895.
https://doi.org/10.1158/1078-0432.CCR-08-0109
Published: 16 June 2008
View article titled, Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia
Open the PDF for Phase I Study of GTI-2040, an Antisense to Ribonucleotide Reductase, in Combination with High-Dose Cytarabine in Patients with Acute Myeloid Leukemia in another window
Journal Articles

Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors

Manisha H. Shah, Philip Binkley, Kenneth Chan, Jim Xiao, Daria Arbogast, Minden Collamore, Yasser Farra, Donn Young, Michael Grever
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (13): 3997–4003.
https://doi.org/10.1158/1078-0432.CCR-05-2689
Published: 03 July 2006
View article titled, Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors
Open the PDF for Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors in another window
Journal Articles

Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatous Polyposis

Rosalind van Stolk, Gary Stoner, William L. Hayton, Kenneth Chan, Barry DeYoung, Laura Kresty, Brian H. Kemmenoe, Paul Elson, Lisa Rybicki, James Church, Kim Provencher, Denise McLain, Ernest Hawk, Ben Fryer, Gary Kelloff, Ram Ganapathi, G. Thomas Budd
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (1): 78–89.
Published: 01 January 2000
View article titled, Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatous Polyposis
Open the PDF for Phase I Trial of Exisulind (Sulindac Sulfone, FGN-1) as a Chemopreventive Agent in Patients with Familial Adenomatous Polyposis in another window